Clinical Research Directory
Browse clinical research sites, groups, and studies.
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Sponsor: Fudan University
Summary
Our study aims to compare 4 months versus 6 months of adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in patients with gastric cancer. Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
Official title: XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
1024
Start Date
2018-01-14
Completion Date
2026-08-15
Last Updated
2026-08-24
Healthy Volunteers
No
Conditions
Interventions
Oxaliplatin
Oxaliplatin 130 mg/m2
Capecitabine
Capecitabine 1000 mg/m2
Locations (10)
Sun Yat-sen University Cancer Center
Guangzhou, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
Jiangsu Cancer Hospital
Nanjing, China
Changhai Hospital
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University
Shanghai, China
Shanghai East Hospital
Shanghai, China
Liaoning Cancer Hospital
Shenyang, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, China